Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - isatuximab, quantity: 500 mg - injection, concentrated - excipient ingredients: water for injections; histidine hydrochloride monohydrate; sucrose; polysorbate 80; histidine - sarclisa is indicated:,? in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi).,? in combination with carfilzomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - isatuximab, quantity: 100 mg - injection, concentrated - excipient ingredients: histidine; histidine hydrochloride monohydrate; polysorbate 80; sucrose; water for injections - sarclisa is indicated:,? in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi).,? in combination with carfilzomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: saccharin; vanillin - treatment of hyperkalaemia.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - calcium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: vanillin; saccharin - calcium resonium is an ion-exchange resin. it is recommended for the treatment of hyperkalaemia associated with anuria and severe oliguria.,it is also used to treat hyperkalaemia in patients requiring dialysis and in patients on regular haemodialysis or on prolonged peritoneal dialysis.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - asparaginase (colaspase) -